Beautiful Virgin Islands

Tuesday, Jun 24, 2025

Pfizer testing COVID treatment pill

Pfizer testing COVID treatment pill

Pfizer, maker of the most widely-used COVID-19 vaccine in the U.S., is testing a potential pill-based treatment for the virus using the same class of medication typically used to treat HIV.
Pfizer announced the beginning of a phase 1 clinical trial using a protease inhibitor pill as a treatment for the virus on Tuesday. News of the trial comes months after Pfizer's COVID-19 vaccine, made in collaboration with the German firm BioNTech, was approved for use and began to be administered in the U.S. and several other countries. The pill, currently dubbed PF-07321332, could offer an additional weapon against the virus as fast-moving mutations threaten to weaken the effectiveness of vaccines.

"Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus," Pfizer's Chief Scientific Officer Mikael Dolsten said in a statement obtained by Newsweek. "Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic."

"We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care," added Dolsten.

The drug has shown activity against the virus that causes COVID-19 in test tube experiments, as well as activity against other types of coronaviruses, with the company saying that the results raise the possibility of "potential use to address future coronavirus threats."

Dolsten touted both the oral medication and the company's previously-developed experimental protease inhibitor treatment designed to be administered to hospitalized COVID-19 patients intravenously, which is currently undergoing phase 1b trials. Dolsten said that that two different approaches offer "the potential to create an end to end treatment paradigm that complements vaccination in cases where disease still occurs."

While none of the vaccines offer total protection against contracting the virus, they have been shown to significantly reduce infections and to be extremely effective in preventing hospitalizations and death. Treatment options could help mitigate concerns posed by the fact that some of the mutations currently making their way around the world have shown a limited amount of resistance to the vaccines, although both Pfizer and Moderna are developing booster shots or new versions of vaccines to combat emerging variants.

As of Tuesday, over 64.6 million people in the U.S. had received at least one dose of the Pfizer-BioNTech vaccine, according to the Centers for Disease Control and Prevention. Moderna's vaccine was not far behind, with around 60.9 million doses administered, while the single-dose Johnson & Johnson vaccine had gone into the arms of just under 2.5 million people.

Protease inhibitors, which block virus reproduction by binding to proteins called protease, were a class of drugs that revolutionized HIV treatment in the mid-1990s. They are key components in the multi-drug "cocktail" therapies that changed HIV from an infection that almost invariably led to AIDS and death to a condition that can typically be survived if treatments are available and used regularly. The drugs are also used against Hepatitis C infections, while researchers have investigated their use as treatments for certain types of cancer and parasitic infections.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
BBC Demands Perplexity AI Immediately Stop Using Its Content
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
Political Turmoil Resurfaces in Belgium Amid Economic Concerns
Fed policymakers divided on timing of interest rate cuts
Trump signals imminent agreement with Harvard University
Inheritance tax referendum alarms Swiss billionaire community
Japan cancels bilateral security meeting amid US defence demands
AI skeptic Emily Bender warns that ‘the emperor has no clothes’
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
Plans to Sell Dutch Embassy in Bangkok Face Local Opposition
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump's $5 Million 'Trump Card' Visa Program Draws Nearly 70,000 Applicants
DGCA Finds No Major Safety Concerns in Air India's Boeing 787 Fleet
Airlines Reroute Flights Amid Expanding Middle East Conflict Zones
Elon Musk's xAI Seeks $9.3 Billion in Funding Amid AI Expansion
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Taiwan Imposes Export Ban on Chips to Huawei and SMIC
Israel has just announced plans to strike Tehran again, and in response, Trump has urged people to evacuate
Netanyahu Signals Potential Regime Change in Iran
Juncker Criticizes EU Inaction on Trump Tariffs
EU Proposes Ban on New Russian Gas Contracts
Analysts Warn Iran May Resort to Unconventional Warfare
Iranian Regime Faces Existential Threat Amid Conflict
×